281
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience

, , , , , , , , , , , , , & show all
Pages 1057-1062 | Received 20 May 2020, Accepted 06 Jul 2020, Published online: 21 Jul 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Farsaneh Sadeghlar, Julia Seelemann, Annabelle Vogt, Christian Möhring, Taotao Zhou, Robert Mahn, Miroslaw Kornek, Veronika Lukacs-Kornek, Noelia Casares, Juan José Lasarte, Pablo Sarobe, Cornelius van Beekum, Hanno Matthaei, Steffen Manekeller, Jörg Kalff, Ingo G.H. Schmidt-Wolf, Christian P. Strassburg & Maria A. Gonzalez-Carmona. (2023) Regulatory T Cell Inhibition by P60 Combined with Adenoviral AFP Transduced Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma. Immunological Investigations 52:8, pages 966-984.
Read now

Articles from other publishers (14)

Qian-Ming Xiang, Ni Jiang, Yue-Feng Liu, Yuan-Biao Wang, De-An Mu, Rong Liu, Lu-Yun Sun, Wei Zhang, Qiang Guo & Kai Li. (2023) Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study. BMC Cancer 23:1.
Crossref
Yen-Hao Chen, Ching-Hua Tsai, Yen-Yang Chen, Chih-Chi Wang, Jing-Houng Wang, Chao-Hung Hung & Yuan-Hung Kuo. (2023) Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. BMC Cancer 23:1.
Crossref
Cheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Xin-Cheng Mao, Jin-Cheng Tian, Jun-Shuai Xue, Si-Yu Tan, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang & Tao Li. (2023) Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients. Cancer Immunology, Immunotherapy 72:7, pages 1957-1969.
Crossref
Xiaofeng Xiong, Qianben Song, Mengjia Jing & Wei Yan. (2023) Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma. Genetics Research 2023, pages 1-26.
Crossref
Bahareh Farasati Far, Dorsa Rabie, Parisa Hemati, Parastoo Fooladpanjeh, Neda Faal Hamedanchi, Nima Broomand Lomer, Arian Karimi Rouzbahani & Mohammad Reza Naimi-Jamal. (2023) Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers 3:1, pages 121-160.
Crossref
Yuwei Liu, Jiahui Pan, Fangbo Gao, Wentao Xu, Hongyu Li & Xingshun Qi. (2022) Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Advances in Therapy 40:2, pages 521-549.
Crossref
Qiang Guo, Si-hua Wang, Yan-mei Ji, Song Tong, Dan Li, Xiang-chao Ding & Chuang-yan Wu. (2022) The Roles and Mechanisms of TRAT1 in the Progression of Non-Small Cell Lung Cancer. Current Medical Science 42:6, pages 1186-1200.
Crossref
Dan Li, Kai Li, Wei Zhang, Kong-Wu Yang, De-An Mu, Guo-Jun Jiang, Rong-Shu Shi & Di Ke. (2022) The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma. Frontiers in Immunology 13.
Crossref
Jiayou Guo, Jiayi Guo, Beibei Cheng, Xingbang Sun, Hongwei Zhang & Jianxin Ma. (2022) Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC. Journal of Healthcare Engineering 2022, pages 1-6.
Crossref
Lixu Zhu & Wenzhi Guo. (2021) Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology 9.
Crossref
Annabelle Vogt, Farsaneh Sadeghlar, Tiyasha H. Ayub, Carlo Schneider, Christian Möhring, Taotao Zhou, Robert Mahn, Alexandra Bartels, Michael Praktiknjo, Miroslaw T. Kornek, Marieta Toma, Ingo G. H. Schmidt-Wolf, Vittorio Branchi, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg & Maria A. Gonzalez-Carmona. (2021) Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma. Cancers 13:13, pages 3375.
Crossref
Carmelo Laface, Mariarita Laforgia, Pasquale Molinari, Ippazio Ugenti, Cosmo Damiano Gadaleta, Camillo Porta & Girolamo Ranieri. (2021) Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers 13:12, pages 3091.
Crossref
Ioannis A. Ziogas, Alexandros P. Evangeliou, Dimitrios Giannis, Muhammad H. Hayat, Konstantinos S. Mylonas, Samer Tohme, David A. Geller, Nahel Elias, Lipika Goyal & Georgios Tsoulfas. (2021) The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. The Oncologist 26:6, pages e1036-e1049.
Crossref
Enfa Zhao, Shimin Chen & Ying Dang. (2021) Development and External Validation of a Novel Immune Checkpoint–Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences 7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.